Geoffrey Owen Littlejohn

18PUBLICATIONS
18CO-AUTHORS
Satisfiability and optimisationAutoimmunityClinical pharmacology and therapeuticsRheumatology and arthritisToxicology (incl. clinical toxicology)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

|Oct 30, 2026
Janus Kinase Inhibitor Use Among People With Inflammatory Disease in Australia.

|Feb 26, 2025
Neuroinflammatory and Immunological Aspects of Fibromyalgia.

Kate Findeisen, Emma Guymer, Geoffrey Littlejohn

|Jan 05, 2025
Real-World Persistence and Effectiveness of Upadacitinib versus Other Janus Kinase Inhibitors and Tumor Necrosis Factor Inhibitors in Australian Patients with Rheumatoid Arthritis.

Peter Youssef, Sabina Ciciriello, Talib Tahir

|Apr 18, 2024
Optimising patient outcomes: temporal trends in remission rates of rheumatoid arthritis patients in the Australian OPAL dataset between 2009 and 2022.

Geoffrey Littlejohn, Nithila Anbumurali, Catherine O'Sullivan

|Mar 08, 2024
Real-world evaluation of persistence, effectiveness and usage patterns of tofacitinib in treatment of psoriatic arthritis in Australia.

Geoffrey Littlejohn, Joanna Leadbetter, Belinda E Butcher

|Nov 27, 2023
Comparative effectiveness of etanercept originator and biosimilar for treating rheumatoid arthritis: implications for cost-savings.

Claire T Deakin, Geoffrey O Littlejohn, Hedley Griffiths

Pageof 3

Frequent Collaborators

7 joint publications

Tegan Smith

7 joint publications

Catherine O'Sullivan

5 joint publications

Paul Bird

5 joint publications

Hedley Griffiths